{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:53:46Z","timestamp":1794275626671,"version":"4.9.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fondation Pierre Mercier pour la Science","award":["x"],"award-info":[{"award-number":["x"]}]},{"DOI":"10.13039\/501100008947","name":"Stiftung Synapsis - Alzheimer Forschung Schweiz AFS","doi-asserted-by":"publisher","award":["x"],"award-info":[{"award-number":["x"]}],"id":[{"id":"10.13039\/501100008947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030L_141179"],"award-info":[{"award-number":["320030L_141179"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic alterations, related to cerebral glucose metabolism, brain insulin resistance, and age-induced mitochondrial dysfunction, play an important role in Alzheimer\u2019s disease (AD) on both the systemic and central nervous system level. To study the extent and significance of these alterations in AD, quantitative metabolomics was applied to plasma and cerebrospinal fluid (CSF) from clinically well-characterized AD patients and cognitively healthy control subjects. The observed metabolic alterations were associated with core pathological processes of AD to investigate their relation with amyloid pathology and tau-related neurodegeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In a case-control study of clinical and biomarker-confirmed AD patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200940) and cognitively healthy controls without cerebral AD pathology (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u200934) with paired plasma and CSF samples, we performed metabolic profiling, i.e., untargeted metabolomics and targeted quantification. Targeted quantification focused on identified deregulated pathways highlighted in the untargeted assay, i.e.\u00a0the TCA cycle, and its anaplerotic pathways, as well as the neuroactive tryptophan and kynurenine pathway.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Concentrations of several TCA cycle and beta-oxidation intermediates were higher in plasma of AD patients, whilst amino acid concentrations were significantly lower. Similar alterations in these energy metabolism intermediates were observed in CSF, together with higher concentrations of creatinine, which were strongly correlated with blood-brain barrier permeability. Alterations of several amino acids were associated with CSF Amyloid\u03b21\u201342. The tryptophan catabolites, kynurenic acid and quinolinic acid, showed significantly higher concentrations in CSF of AD patients, which, together with other tryptophan pathway intermediates, were correlated with either CSF Amyloid\u03b21\u201342, or tau and phosphorylated Tau-181.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study revealed AD-associated systemic dysregulation of nutrient sensing and oxidation and CNS-specific alterations in the neuroactive tryptophan pathway and (phospho)creatine degradation. The specific association of amino acids and tryptophan catabolites with AD CSF biomarkers suggests a close relationship with core AD pathology.<\/jats:p>\n                    <jats:p>Our findings warrant validation in independent, larger cohort studies as well as further investigation of factors such as gender and APOE genotype, as well as of other groups, such as preclinical AD, to identify metabolic alterations as potential intervention targets.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-019-0551-7","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T18:02:39Z","timestamp":1574964159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":227,"title":["Systemic and central nervous system metabolic alterations in Alzheimer\u2019s disease"],"prefix":"10.1186","volume":"11","author":[{"given":"Vera","family":"van der Velpen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tony","family":"Teav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H\u00e9ctor","family":"Gallart-Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Mehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Konz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aikaterini","family":"Oikonomidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendoline","family":"Peyratout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Delorenzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julijana","family":"Ivanisevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Popp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"issue":"11","key":"551_CR1","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1586\/ern.10.136","volume":"10","author":"K Herholz","year":"2010","unstructured":"Herholz K. Cerebral glucose metabolism in preclinical and prodromal Alzheimer\u2019s disease. Expert Rev Neurother. 2010;10(11):1667\u201373.","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"551_CR2","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1172\/JCI59903","volume":"122","author":"K Talbot","year":"2012","unstructured":"Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316\u201338.","journal-title":"J Clin Invest"},{"issue":"1","key":"551_CR3","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/JAD-2005-7107","volume":"7","author":"E Steen","year":"2005","unstructured":"Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63\u201380.","journal-title":"J Alzheimers Dis"},{"issue":"9","key":"551_CR4","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1007\/s12035-015-9515-5","volume":"53","author":"C Cadonic","year":"2016","unstructured":"Cadonic C, Sabbir MG, Albensi BC. Mechanisms of mitochondrial dysfunction in Alzheimer\u2019s disease. Mol Neurobiol. 2016;53(9):6078\u201390.","journal-title":"Mol Neurobiol"},{"key":"551_CR5","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.exger.2017.10.013","volume":"100","author":"J Mathys","year":"2017","unstructured":"Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia. Exp Gerontol. 2017;100:45\u201353.","journal-title":"Exp Gerontol"},{"key":"551_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.dadm.2017.07.006","volume":"8","author":"FA de Leeuw","year":"2017","unstructured":"de Leeuw FA, Peeters CFW, Kester MI, Harms AC, Struys EA, Hankemeier T, et al. Blood-based metabolic signatures in Alzheimer's disease. Alzheimers Dement (Amst). 2017;8:196\u2013207.","journal-title":"Alzheimers Dement (Amst)"},{"issue":"7424","key":"551_CR7","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11708","volume":"491","author":"JK Nicholson","year":"2012","unstructured":"Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC. Metabolic phenotyping in clinical and surgical environments. Nature. 2012;491(7424):384\u201392.","journal-title":"Nature."},{"issue":"7","key":"551_CR8","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrd.2016.32","volume":"15","author":"DS Wishart","year":"2016","unstructured":"Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016;15(7):473\u201384.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"551_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/nrm3314","volume":"13","author":"GJ Patti","year":"2012","unstructured":"Patti GJ, Yanes O, Siuzdak G. Innovation: metabolomics: the apogee of the omics trilogy. Nat Rev Mol Cell Biol. 2012;13(4):263\u20139.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"551_CR10","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrm.2016.25","volume":"17","author":"Caroline H. Johnson","year":"2016","unstructured":"Johnson CH, Ivanisevic J, Siuzdak G. Metabolomics: Beyond Biomarkers and Towards Mechanisms. Nat Rev Mol Cell Biol. 2016;17(7):451\u20139.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"6","key":"551_CR11","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41580-019-0108-4","volume":"20","author":"Markus M. Rinschen","year":"2019","unstructured":"Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019;20(6):353\u201367.","journal-title":"Nature Reviews Molecular Cell Biology"},{"issue":"3","key":"551_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11481-015-9621-1","volume":"10","author":"J Ivanisevic","year":"2015","unstructured":"Ivanisevic J, Siuzdak G. The role of metabolomics in brain metabolism research. J NeuroImmune Pharmacol. 2015;10(3):391\u20135.","journal-title":"J NeuroImmune Pharmacol"},{"issue":"5","key":"551_CR13","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.18632\/aging.100961","volume":"8","author":"J Ivanisevic","year":"2016","unstructured":"Ivanisevic J, Stauch KL, Petrascheck M, Benton HP, Epstein AA, Fang M, et al. Metabolic drift in the aging brain. Aging (Albany NY). 2016;8(5):1000\u201320.","journal-title":"Aging (Albany NY)"},{"key":"551_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-7592-1_1","volume":"1730","author":"J Ivanisevic","year":"2018","unstructured":"Ivanisevic J, Thomas A. Metabolomics as a tool to understand pathophysiological processes. Methods Mol Biol. 2018;1730:3\u201328.","journal-title":"Methods Mol Biol"},{"issue":"2","key":"551_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1021\/acs.jproteome.5b01020","volume":"15","author":"G Paglia","year":"2016","unstructured":"Paglia G, Stocchero M, Cacciatore S, Lai S, Angel P, Alam MT, et al. Unbiased Metabolomic investigation of Alzheimer's disease brain points to Dysregulation of mitochondrial aspartate metabolism. J Proteome Res. 2016;15(2):608\u201318.","journal-title":"J Proteome Res"},{"issue":"6","key":"551_CR16","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.jalz.2018.01.003","volume":"14","author":"Juho Tynkkynen","year":"2018","unstructured":"Tynkkynen J, Chouraki V, van der Lee SJ, Hernesniemi J, Yang Q, Li S, et al. Association of branched-chain amino acids and other circulating metabolites with risk of incident dementia and Alzheimer's disease: a prospective study in eight cohorts. Alzheimers Dement. 2018;14(6):723\u201333.","journal-title":"Alzheimer's & Dementia"},{"issue":"9","key":"551_CR17","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.jalz.2017.01.020","volume":"13","author":"JB Toledo","year":"2017","unstructured":"Toledo JB, Arnold M, Kastenmuller G, Chang R, Baillie RA, Han X, et al. Metabolic network failures in Alzheimer's disease: a biochemical road map. Alzheimers Dement. 2017;13(9):965\u201384.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"551_CR18","doi-asserted-by":"publisher","first-page":"e63644","DOI":"10.1371\/journal.pone.0063644","volume":"8","author":"E Trushina","year":"2013","unstructured":"Trushina E, Dutta T, Persson XM, Mielke MM, Petersen RC. Identification of altered metabolic pathways in plasma and CSF in mild cognitive impairment and Alzheimer's disease using metabolomics. PLoS One. 2013;8(5):e63644.","journal-title":"PLoS One"},{"issue":"1","key":"551_CR19","doi-asserted-by":"publisher","first-page":"e1002482","DOI":"10.1371\/journal.pmed.1002482","volume":"15","author":"VR Varma","year":"2018","unstructured":"Varma VR, Oommen AM, Varma S, Casanova R, An Y, Andrews RM, et al. Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: a targeted metabolomics study. PLoS Med. 2018;15(1):e1002482.","journal-title":"PLoS Med"},{"issue":"1","key":"551_CR20","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13195-017-0270-x","volume":"9","author":"L Dayon","year":"2017","unstructured":"Dayon L, Guiraud SP, Corthesy J, Da Silva L, Migliavacca E, Tautvydaite D, et al. One-carbon metabolism, cognitive impairment and CSF measures of Alzheimer pathology: homocysteine and beyond. Alzheimers Res Ther. 2017;9(1):43.","journal-title":"Alzheimers Res Ther"},{"key":"551_CR21","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jpsychires.2016.12.024","volume":"90","author":"D Tautvydaite","year":"2017","unstructured":"Tautvydaite D, Antonietti JP, Henry H, von Gunten A, Popp J. Relations between personality changes and cerebrospinal fluid biomarkers of Alzheimer's disease pathology. J Psychiatr Res. 2017;90:12\u201320.","journal-title":"J Psychiatr Res"},{"key":"551_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.bbi.2017.01.020","volume":"62","author":"J Popp","year":"2017","unstructured":"Popp J, Oikonomidi A, Tautvydaite D, Dayon L, Bacher M, Migliavacca E, et al. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. Brain Behav Immun. 2017;62:203\u201311.","journal-title":"Brain Behav Immun"},{"key":"551_CR23","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.aca.2018.04.002","volume":"1037","author":"H\u00e9ctor Gallart-Ayala","year":"2018","unstructured":"Gallart-Ayala H, Konz I, Mehl F, Teav T, Oikonomidi A, Peyratout G, et al. A global HILIC-MS approach to measure polar human cerebrospinal fluid metabolome: exploring gender-associated variation in a cohort of elderly cognitively healthy subjects. Anal Chim Acta. 2018;1037:327\u201337.","journal-title":"Analytica Chimica Acta"},{"key":"551_CR24","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nmeth.4260","volume":"14","author":"T Huan","year":"2017","unstructured":"Huan T, Forsberg EM, Rinehart D, Johnson CH, Ivanisevic J, Benton HP, et al. Systems biology guided by XCMS online metabolomics. Nat Methods. 2017;14:461.","journal-title":"Nat Methods"},{"issue":"5","key":"551_CR25","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1021\/acs.analchem.7b04424","volume":"90","author":"C Guijas","year":"2018","unstructured":"Guijas C, Montenegro-Burke JR, Domingo-Almenara X, Palermo A, Warth B, Hermann G, et al. METLIN: a technology platform for identifying Knowns and unknowns. Anal Chem. 2018;90(5):3156\u201364.","journal-title":"Anal Chem"},{"issue":"11","key":"551_CR26","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.chembiol.2014.09.016","volume":"21","author":"J Ivanisevic","year":"2014","unstructured":"Ivanisevic J, Epstein AA, Kurczy ME, Benton PH, Uritboonthai W, Fox HS, et al. Brain region mapping using global metabolomics. Chem Biol. 2014;21(11):1575\u201384.","journal-title":"Chem Biol"},{"issue":"16","key":"551_CR27","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1093\/bioinformatics\/btu203","volume":"30","author":"H Tsugawa","year":"2014","unstructured":"Tsugawa H, Kanazawa M, Ogiwara A, Arita M. MRMPROBS suite for metabolomics using large-scale MRM assays. Bioinformatics. 2014;30(16):2379\u201380.","journal-title":"Bioinformatics."},{"key":"551_CR28","first-page":"14 0 1","volume":"55","author":"J Xia","year":"2016","unstructured":"Xia J, Wishart DS. Using MetaboAnalyst 3.0 for Comprehensive Metabolomics Data Analysis. Curr Protoc Bioinformatics. 2016;55:14 0 1\u20130 91.","journal-title":"Curr Protoc Bioinformatics"},{"issue":"18","key":"551_CR29","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1093\/bioinformatics\/btq418","volume":"26","author":"DS Wishart","year":"2010","unstructured":"Wishart DS, Xia J. MetPA: a web-based metabolomics tool for pathway analysis and visualization. Bioinformatics. 2010;26(18):2342\u20134.","journal-title":"Bioinformatics."},{"issue":"4","key":"551_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535\u201362.","journal-title":"Alzheimers Dement"},{"issue":"5","key":"551_CR31","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/00365517709091496","volume":"37","author":"G Tibbling","year":"1977","unstructured":"Tibbling G, Link H, \u00d6hman S. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. Scand J Clin Lab Invest. 1977;37(5):385\u201390.","journal-title":"Scand J Clin Lab Invest"},{"issue":"6","key":"551_CR32","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.jalz.2019.03.004","volume":"15","author":"Min Kim","year":"2019","unstructured":"Kim M, Snowden S, Suvitaival T, Ali A, Merkler DJ, Ahmad T, et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. Alzheimers Dementia. 2019;15(6):817\u201327.","journal-title":"Alzheimer's & Dementia"},{"issue":"3","key":"551_CR33","doi-asserted-by":"publisher","first-page":"493-507.e6","DOI":"10.1016\/j.cmet.2019.06.005","volume":"30","author":"Sung Hoon Baik","year":"2019","unstructured":"Baik SH, Kang S, Lee W, Choi H, Chung S, Kim JI, et al. A Breakdown in Metabolic Reprogramming Causes Microglia Dysfunction in Alzheimer's Disease. Cell Metab. 2019;30(3):493\u2013507 e6.","journal-title":"Cell Metabolism"},{"issue":"5","key":"551_CR34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.cmet.2015.08.016","volume":"22","author":"M Ishii","year":"2015","unstructured":"Ishii M, Iadecola C. Metabolic and non-cognitive manifestations of Alzheimer's disease: the hypothalamus as both culprit and target of pathology. Cell Metab. 2015;22(5):761\u201376.","journal-title":"Cell Metab"},{"key":"551_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.nicl.2015.03.016","volume":"8","author":"D Val-Laillet","year":"2015","unstructured":"Val-Laillet D, Aarts E, Weber B, Ferrari M, Quaresima V, Stoeckel LE, et al. Neuroimaging and neuromodulation approaches to study eating behavior and prevent and treat eating disorders and obesity. Neuroimage Clin. 2015;8:1\u201331.","journal-title":"Neuroimage Clin"},{"issue":"4","key":"551_CR36","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14(4):388\u2013405.","journal-title":"Lancet Neurol"},{"key":"551_CR37","volume-title":"Biochemistry","author":"JMTJ Berg","year":"2002","unstructured":"Berg JMTJ, Stryer L. Biochemistry. 5th ed. New York: W H Freeman; 2002.","edition":"5"},{"key":"551_CR38","doi-asserted-by":"publisher","first-page":"5472792","DOI":"10.1155\/2017\/5472792","volume":"2017","author":"JW Griffin","year":"2017","unstructured":"Griffin JW, Bradshaw PC. Amino acid catabolism in Alzheimer's disease brain: friend or foe? Oxidative Med Cell Longev. 2017;2017:5472792.","journal-title":"Oxidative Med Cell Longev"},{"issue":"10","key":"551_CR39","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nrendo.2015.129","volume":"11","author":"CS McCoin","year":"2015","unstructured":"McCoin CS, Knotts TA, Adams SH. Acylcarnitines--old actors auditioning for new roles in metabolic physiology. Nat Rev Endocrinol. 2015;11(10):617\u201325.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"551_CR40","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3233\/JAD-2009-1187","volume":"18","author":"J Popp","year":"2009","unstructured":"Popp J, Lewczuk P, Linnebank M, Cvetanovska G, Smulders Y, Kolsch H, et al. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. J Alzheimers Dis. 2009;18(4):819\u201328.","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"551_CR41","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1152\/physrev.2000.80.3.1107","volume":"80","author":"M Wyss","year":"2000","unstructured":"Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107\u2013213.","journal-title":"Physiol Rev"},{"issue":"6","key":"551_CR42","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1046\/j.1471-4159.2000.0742520.x","volume":"74","author":"M Aksenov","year":"2000","unstructured":"Aksenov M, Aksenova M, Butterfield DA, Markesbery WR. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J Neurochem. 2000;74(6):2520\u20137.","journal-title":"J Neurochem"},{"key":"551_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/IJTR.S13958","volume":"7","author":"M Wennstrom","year":"2014","unstructured":"Wennstrom M, Nielsen HM, Orhan F, Londos E, Minthon L, Erhardt S. Kynurenic acid levels in cerebrospinal fluid from patients with Alzheimer's disease or dementia with lewy bodies. Int J Tryptophan Res. 2014;7:1\u20137.","journal-title":"Int J Tryptophan Res"},{"key":"551_CR44","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3389\/fnins.2014.00012","volume":"8","author":"BM Campbell","year":"2014","unstructured":"Campbell BM, Charych E, Lee AW, Moller T. Kynurenines in CNS disease: regulation by inflammatory cytokines. Front Neurosci. 2014;8:12.","journal-title":"Front Neurosci"},{"issue":"1","key":"551_CR45","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4103\/1673-5374.198971","volume":"12","author":"N Braidy","year":"2017","unstructured":"Braidy N, Grant R. Kynurenine pathway metabolism and neuroinflammatory disease. Neural Regen Res. 2017;12(1):39\u201342.","journal-title":"Neural Regen Res"},{"key":"551_CR46","doi-asserted-by":"crossref","unstructured":"Sharma R, Razdan K, Bansal Y, Kuhad A. Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease. Expert Opin Ther Targets. 2018:1\u201319.","DOI":"10.1080\/14728222.2018.1524877"},{"issue":"2","key":"551_CR47","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3233\/JAD-170929","volume":"62","author":"D Zadori","year":"2018","unstructured":"Zadori D, Veres G, Szalardy L, Klivenyi P, Vecsei L. Alzheimer's disease: recent concepts on the relation of mitochondrial disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines. J Alzheimers Dis. 2018;62(2):523\u201347.","journal-title":"J Alzheimers Dis"},{"issue":"Pt B","key":"551_CR48","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.neuropharm.2016.03.024","volume":"112","author":"MD Lovelace","year":"2017","unstructured":"Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, et al. Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology. 2017;112(Pt B):373\u201388.","journal-title":"Neuropharmacology"},{"issue":"7","key":"551_CR49","doi-asserted-by":"publisher","first-page":"e6344","DOI":"10.1371\/journal.pone.0006344","volume":"4","author":"A Rahman","year":"2009","unstructured":"Rahman A, Ting K, Cullen KM, Braidy N, Brew BJ, Guillemin GJ. The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One. 2009;4(7):e6344.","journal-title":"PLoS One"},{"key":"551_CR50","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.1038\/tp.2013.18","volume":"3","author":"R Kaddurah-Daouk","year":"2013","unstructured":"Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, et al. Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry. 2013;3:e244.","journal-title":"Transl Psychiatry"},{"key":"551_CR51","doi-asserted-by":"crossref","unstructured":"Arnold M, Nho K, Kueider-Paisley A, Massaro T, Brauner B, MahmoudianDehkordi S, et al. The Alzheimer\u2019s Disease Metabolome: Effects of Sex and APOE \u03b54 genotype. bioRxiv. 2019:585455.","DOI":"10.1101\/585455"},{"issue":"Pt B","key":"551_CR52","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.neuropharm.2018.01.044","volume":"136","author":"AI Duarte","year":"2018","unstructured":"Duarte AI, Santos MS, Oliveira CR, Moreira PI. Brain insulin signalling, glucose metabolism and females\u2019 reproductive aging: A dangerous triad in Alzheimer's disease. Neuropharmacology. 2018;136(Pt B):223\u201342.","journal-title":"Neuropharmacology"},{"key":"551_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.neurobiolaging.2016.02.011","volume":"42","author":"L Zhao","year":"2016","unstructured":"Zhao L, Mao Z, Woody SK, Brinton RD. Sex differences in metabolic aging of the brain: insights into female susceptibility to Alzheimer's disease. Neurobiol Aging. 2016;42:69\u201379.","journal-title":"Neurobiol Aging"},{"issue":"6","key":"551_CR54","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.chom.2018.05.003","volume":"23","author":"A Agus","year":"2018","unstructured":"Agus A, Planchais J, Sokol H. Gut microbiota regulation of tryptophan metabolism in health and disease. Cell Host Microbe. 2018;23(6):716\u201324.","journal-title":"Cell Host Microbe"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-019-0551-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-019-0551-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,17]],"date-time":"2022-04-17T06:16:53Z","timestamp":1650176213000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-019-0551-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["551"],"URL":"https:\/\/doi.org\/10.1186\/s13195-019-0551-7","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"4 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Ethics Committee of the canton of Vaud, Switzerland, approved the study, and written informed consent was received from all participants before inclusion into the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JP received consultation honoraria from Nestle Institute of Health Sciences, Innovation Campus, EPFL, Lausanne, Switzerland, Ono Pharma and from Fujirebio Europe. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"93"}}